Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.
about
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv miceEmergence of drug resistance is associated with an increased risk of death among patients first starting HAARTStudies of retroviral infection in humanized miceAntibacterial effect of human V gamma 2V delta 2 T cells in vivoTarget cell APOBEC3C can induce limited G-to-A mutation in HIV-1IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivoHIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection.Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells.Chapter 12. Placental remodeling of the uterine vasculature.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.Assessment of thymic activity in human immunodeficiency virus-negative and -positive adolescents by real-time PCR quantitation of T-cell receptor rearrangement excision circles.Human retroviruses after 20 years: a perspective from the past and prospects for their future control.Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.In Vivo validation of a bioinformatics based tool to identify reduced replication capacity in HIV-1.Cytotrophoblast induction of arterial apoptosis and lymphangiogenesis in an in vivo model of human placentationThe aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice.Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infectionImpaired infectivity of ritonavir-resistant HIV is rescued by heat shock protein 90AB1.High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.Human immunodeficiency virus persistence and production in T-cell developmentT-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis.Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.Impaired surfactant production by alveolar epithelial cells in a SCID-hu lung mouse model of congenital human cytomegalovirus infection.Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.Clinical significance of human immunodeficiency virus type 1 replication fitness.HIV protease inhibitors: recent clinical trials and recommendations on use.Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch.Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.Positive regulation of CXCR4 expression and signaling by interleukin-7 in CD4+ mature thymocytes correlates with their capacity to favor human immunodeficiency X4 virus replication.Is average adherence to HIV antiretroviral therapy enough?Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.Hepatitis C virus infection in human liver tissue engrafted in mice with an infectious molecular clone.Viral load in tissues during the early and chronic phase of non-pathogenic SIVagm infection.Persistent HIV-1 replication does not explain low levels of T-cell interferon-gamma mRNA and elevated serum NO(2) (-)/NO(3) (-) in patients with stable CD4 T-cell responses to HAART.Immunological and virological features of HIV-infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor-based therapy.Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy.Editorial: developmental regulation of P-glycoprotein and HIV therapy: spare the thymus but spoil the child?Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.
P2860
Q21092230-74F0CD3E-0687-4471-87DC-7CDB247FB596Q21563427-F47A32A2-3D47-4F61-9745-861A6B77673EQ26849806-7346D8CD-1D62-43C2-8E24-C5B71E7F6D78Q28363497-C1C671FB-2DD3-4A44-B4AF-0DBC20FA6C3FQ28469342-A4507132-6B89-4865-88AE-7744ABD12726Q33533290-7303B3A9-3744-4894-87D7-5E792B2A06A2Q33721788-27E6B4C8-5C22-477F-8F3D-9711973C9BA2Q33760825-C8FEB319-1BFA-4A74-9B6D-4DFC9F705733Q33801683-D2C3ACE7-E5D2-4D49-A761-10BED7EFDC0EQ33906239-1A6EBBBD-28F5-42CC-BAE3-02B687438FCEQ33924628-513B1DE9-8B97-4328-819F-4BC0D59CAA9FQ34012585-E32AEF11-AB52-4A8F-BBD0-F3804E76E905Q34779227-A9140E79-F6D3-4435-8B26-36B699AE5554Q34792498-A9B373AC-9FA1-4C9A-9A0B-BC1B2D7875E2Q34976619-52776AF1-E2E5-433F-872C-7A9AF8D881C6Q34991044-AC10EF8F-3E96-492C-96D5-BB94BD94FE5DQ35039896-33D29380-B133-4717-B916-725F4F5AF0E4Q35102332-82A3138C-8998-4448-8C53-4FEB42602707Q35104695-CDCA9C5B-BAFE-49C9-A0E3-AB5DE08E45ADQ35107346-80271178-1F00-4F1F-A48E-97A629DEEB50Q35156558-D2858377-F689-4B14-8B44-51F9ED285D7AQ35160655-55E241EA-C3E2-40FE-8B9F-ACAD9CBD3781Q35543827-32AC1DB8-F2BB-4454-AE90-607175549A70Q36132255-1C73E798-23C6-4B04-AEE5-54F5B5316F8DQ36397429-0D57497D-AF82-4069-9602-24FEA4104092Q36769221-1EB7B8C3-99FD-4E48-8A53-02125E19E388Q36969857-E7870D1A-E518-4418-8AE3-C0C59055FB28Q37519715-5C536CC7-1654-4BBE-8140-FEA78DF215CAQ39528150-47EA44EF-5E43-4179-B8D5-D44F201FC4E5Q39748924-682DF2BF-BDAD-409A-9D23-6C9BD527F4D3Q39748962-5CB725B9-9A5E-4720-8E6D-1D271A62B945Q42347783-0DC977ED-95CC-4ABB-A7D9-EFE929C78CF6Q42931192-8D57FD5B-4F5A-4169-96C7-558001E2C677Q42985608-2401F9B1-402C-4757-91AF-C864AFC98013Q43702789-72B04ACB-9068-4F9E-A780-0DB6FC2A8A63Q44450348-DDE377AE-2FFC-47A0-AEB4-E478A8DB857BQ45252704-7977F68B-9A70-4467-ABAA-C00F051FACDEQ45399547-D8FC8948-694A-4B1E-86AD-EECD46BF4EEEQ51852014-ECB516F7-F8FA-4A6A-8D9F-59C31544FE5FQ54247474-3C5A998A-1D53-46B2-8D47-89038837DAE5
P2860
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.
@en
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.
@nl
type
label
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.
@en
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.
@nl
prefLabel
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.
@en
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.
@nl
P2093
P50
P356
P1433
P1476
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
@en
P2093
Liegler TJ
Linquist-Stepps VD
Stoddart CA
P2888
P304
P356
10.1038/89090
P407
P577
2001-06-01T00:00:00Z